Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 13,471 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Endocrine Disorders Clear all
Recruiting No phase listed Observational

Capability Assessment for Diet and Activity (CADA) Model for Diabetes

NCT06631105
View directory record Official record
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Nov 10, 2026, 4:34 PM EST
Withdrawn Phase 2 Interventional

Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma

NCT01045941
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Gemcitabine/Gemzar, Laparoscopic Distal pancreatectomy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Nov 10, 2026, 4:34 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay

NCT01750203
View directory record Official record
Conditions
Chronic Wounds With Different Etiologies
Interventions
Swabs
Other
Lead sponsor
Systagenix Wound Management
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Nov 10, 2026, 4:34 PM EST
Completed Phase 3 Interventional Results available

Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism

NCT02504541
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Nov 10, 2026, 4:34 PM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care

NCT00787839
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Prediabetic State
Interventions
Glucose challenge test, Glucose tolerance test
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Nov 10, 2026, 4:34 PM EST
Completed Phase 1 Interventional

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

NCT03000257
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Venetoclax, Rovalpituzumab Tesirine, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
5
States / cities
La Jolla, California • Chicago, Illinois • Huntersville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Nov 10, 2026, 4:34 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

NCT04404595
View directory record Official record
Conditions
Gastric Cancer, Pancreatic Cancer
Interventions
CT041
Biological
Lead sponsor
CARsgen Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 76 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Nov 10, 2026, 4:34 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

The CARING Study: Creating and Restoring Health Through Nutrition Guidance

NCT05795439
View directory record Official record
Conditions
Type2diabetes, Type 2 Diabetes Treated With Insulin
Interventions
Low-fat, vegan diet
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 10, 2026, 4:34 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

NCT00001595
View directory record Official record
Conditions
Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
Interventions
Tissue specimen collection, MRI
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 70 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1997
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 10, 2026, 4:34 PM EST
Active, not recruiting Phase 2 Interventional

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

NCT04594772
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Folfirinox, Gemcitabine, radiation therapy, Pancreatectomy
Drug · Radiation · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Tucson, Arizona • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 10, 2026, 4:34 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Effect of Physical Activity on Metabolic Syndrome in Pregnancy & Fetal Outcome

NCT00647595
View directory record Official record
Conditions
Obesity, Pregnancy, Diabetes Mellitus
Interventions
Experimental group
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Joint Base Lewis McChord, Washington
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Nov 10, 2026, 4:34 PM EST
Enrolling by invitation No phase listed Observational

Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)

NCT07197775
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Type2Diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes, Diabetes
Interventions
Not listed
Lead sponsor
Endogenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Quincy, Massachusetts • Raleigh, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 10, 2026, 4:34 PM EST
Not yet recruiting Phase 1Phase 2 Interventional

Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol Secretion

NCT07925801
View directory record Official record
Conditions
Type 2 Diabetes, Hypercortisolism
Interventions
Relacorilant
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 10, 2026, 4:34 PM EST
Terminated No phase listed Observational

Effectiveness of Automated Inpatient Endocrinology Consultation for Osteoporotic Hip Fracture

NCT00643175
View directory record Official record
Conditions
Osteoporosis
Interventions
Automated follow up
Behavioral
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2009 · Synced Nov 10, 2026, 4:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Whole Prediabetes: A Family-Centered Whole Foods Diet in Adults With Prediabetes and Their Offspring

NCT05483972
View directory record Official record
Conditions
PreDiabetes
Interventions
Whole Prediabetes Diet Intervention
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
25 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Nov 10, 2026, 4:34 PM EST
Completed No phase listed Observational

Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food

NCT00818077
View directory record Official record
Conditions
Type 2 Diabetes, Currently Taking Metformin
Interventions
Continuous Glucose Monitoring of Carbohydrate Intake
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Nov 10, 2026, 4:34 PM EST
Recruiting Phase 3 Interventional

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

NCT07664553
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Elecoglipron, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Little Rock, Arkansas • Sacramento, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 10, 2026, 4:34 PM EST
Completed Phase 2 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

NCT00467051
View directory record Official record
Conditions
Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Malignant Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Yolk Sac Tumor, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor, Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor, Testicular Yolk Sac Tumor
Interventions
Carboplatin, Filgrastim, Ifosfamide, Laboratory Biomarker Analysis, Paclitaxel
Drug · Biological · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
85
States / cities
Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Nov 10, 2026, 4:34 PM EST
Completed Phase 1Phase 2 Interventional Results available

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

NCT02487095
View directory record Official record
Conditions
Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms, Carcinoma, Neuroendocrine, Extrapulmonary Small Cell Cancer
Interventions
Topotecan, VX-970 (M6620)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Nov 10, 2026, 4:34 PM EST
Not listed Phase 3 Interventional Results available

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

NCT03252353
View directory record Official record
Conditions
Acromegaly
Interventions
octreotide capsules, Matching placebo
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Nov 10, 2026, 4:34 PM EST
Completed Phase 2 Interventional Results available

Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer

NCT01031381
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
RAD001, bevacizumab
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Nov 10, 2026, 4:34 PM EST
Completed Phase 3 Interventional Results available

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

NCT00082381
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide (AC2993), Insulin glargine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
21
States / cities
San Diego, California • San Mateo, California • Fort Myers, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Nov 10, 2026, 4:34 PM EST
Completed Phase 2 Interventional Results available

Calcium Channel Blockade in Primary Aldosteronism

NCT04179019
View directory record Official record
Conditions
Primary Aldosteronism, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Interventions
Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Nov 10, 2026, 4:34 PM EST
Terminated Not applicable Interventional Results available

Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

NCT00428207
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Aspart versus Insulin Lispro, Insulin Lispro versus Insulin Aspart
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 10, 2026, 4:34 PM EST